Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Nathan Connell: 100 Years of von Willebrand Disease – From the Åland Islands to Precision Care
Nathan Connell/LinkedIn
Feb 11, 2026, 11:07

Nathan Connell: 100 Years of von Willebrand Disease – From the Åland Islands to Precision Care

Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn about his recent article published in American Society of Hematology, adding:

”100 Years of von Willebrand Disease: From the Åland Islands to Modern Precision Care

In 1926, Erik von Willebrand described a mysterious ‘hereditary pseudohemophilia’ in a young girl from the Åland Islands. Now, 100 years later, I am honored to share my latest publication in Blood Advances, “Treatment of von Willebrand Disease,” part of a special series celebrating this clinical centenary.

It is humbling to look back at how far we’ve come—from the first use of plasma infusions to the modern era of recombinant factors and personalized prophylaxis. While VWD remains the most common inherited bleeding disorder, its management is more nuanced than ever.

In this comprehensive review, I explore the shifting paradigms in care and the current standards that define ‘best practice’ in 2026:

  • The Desmopressin Standard: Why a careful therapeutic trial and monitoring are non-negotiable, and how we navigate the nuances of tachyphylaxis and hyponatremia risk.
  • The Evolution of Replacement Therapy: A comparison of plasma-derived vs. recombinant VWF concentrates, and how they are best utilized for both surgical and emergency management.
  • The Prophylaxis Shift: We are moving beyond ‘on-demand’ treatment. For people with type 3 VWD and severe type 1 or 2 VWD, prophylaxis should be the gold standard to prevent joint bleeds and life-threatening mucosal hemorrhage.
  • Closing the Gap for Women: Highlighting the vital role of adjunctive therapies (like antifibrinolytics and hormonal options) in managing heavy menstrual bleeding.
  • Future Horizons: A look at what’s next—including long-acting products and the potential of emicizumab—as we strive for a near-normal quality of life for every patient.

A century ago, those with this bleeding disorder faced a lifetime of uncertainty. Today, our goal is to adopt a multidisciplinary, personalized approach to treatment. I hope this review serves as a valuable roadmap for clinicians navigating these complex treatment decisions.”

Title: Treatment of von Willebrand disease

Authors: Nathan T. Connell

Read the Full Article on American Society of Hematology.

Nathan Connell: 100 Years of von Willebrand Disease - From the Åland Islands to Precision Care

Stay updated on all scientific advances with Hemostasis Today.

American Society of Hematology Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Nathan Connell thrombosis Von Willebrand Disease
NewsFeed